Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to $381
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on Biogen (NASDAQ:BIIB) and raises the price target from $363 to $381.
September 05, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on Biogen and raises the price target from $363 to $381, indicating a positive outlook for the stock.
The raised price target by Morgan Stanley indicates their belief in the stock's potential to perform well in the short term. This could lead to increased investor confidence and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100